Pfizer survey finds disconnect between RA patients and doctors

Pfizer yesterday announced the results of its global rheumatoid arthritis (RA) survey, the second phase of which examined doctor and patient communication and how it affects RA disease management.

The second phase incorporated responses from more than 1,700 rheumatologists in 15 countries with 3,900 RA patients' responses taken from a 2015 global survey. Combining the responses from two surveys reveals that while approximately three-quarters of the doctors establish treatment and management goals, many patients are not aware of the doctors' goals.

“Physicians are likely discussing both goals and disease management plans with their patients; however, patients may not be aware due to differences in the language or terminology used when discussing these measures,” RA NarRAtive Advisory Panel Co-Chair Dr. Alan Gibofsky said. “These potential communication gaps confirm the need for a joint commitment to improved dialogue focused on changing the narrative around the management of RA.”

Part of the disconnect may lie in the different perspectives of doctors and patients. While RA patients who participate in treatment decisions are generally more satisfied, more than half of the patients are uncomfortable sharing their concerns and fears with their doctors. In addition, more than half of the patients are concerned with their quality of life. Doctors tend to be more concerned with medication regimes and possible side effects.

“Closing the gaps in communication between patient and physician can help improve RA management,” Pfizer EVP and Chief Medical Officer Dr. Freda Lewis-Hall said. “We look forward to applying the learnings of the RA NarRAtive survey to tools and resources that can facilitate effective dialogue.”